---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-22-001152"
form_type: "8-K"
ticker: "ARCT"
cik: "0001768224"
company_name: "Arcturus Therapeutics Holdings Inc."
filed_at: "2022-08-09T23:59:59+00:00"
generated_at: "2026-06-24T02:12:44.057011+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Arcturus Q2 revenue $27.1M, net loss $0.82/share; ARCT-154 booster shows durable Omicron response

## Summary
- Revenue $27.1M (vs $2.0M Q2 2021); net loss $21.6M ($0.82/sh) improved from $54.6M ($2.07/sh) year ago.
- ARCT-154 booster: 44-fold (BA.1) and 39-fold (BA.2) neutralizing antibody GMFR at Day 91.
- ARCT-810 gets EU Orphan Medicinal Product Designation for OTC deficiency; Phase 2 study enrolling.
- ARCT-154 EUA in Vietnam delayed to Q4 2022; registrational booster study expected Q4 2022.
- Cash $283.5M at June 30, down from $370.5M at Dec 2021; expected to fund ops into late 2023.

## SEC filing metadata
- accession: 0001193805-22-001152
- form_type: 8-K
- ticker: ARCT
- cik: 0001768224
- company_name: Arcturus Therapeutics Holdings Inc.
- filed_at: 2022-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768224/000119380522001152/0001193805-22-001152-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768224/000119380522001152/e621864_8k-arct.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-22-001152
- JSON: https://secwatch.observer/filing/0001193805-22-001152.json
- Plain text: https://secwatch.observer/filing/0001193805-22-001152.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.